Stock Detail
ANTIGENICS INC
Sector: Biotechnology
Latest Quote @ Sun May 5 00:18:26 (15 min delayed)
| N/A |
N/A |
$4.07 |
-0.05 |
-1.21% |
|
Last Day's Data
| $4.07 |
$4.19 |
$0.00 |
0.00% |
0.00 |
$4.12 |
| $4.09 |
$4.05 |
104,932.00 |
102.97M |
94,402.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 4.24 |
4.15 |
4.10 |
4.01 |
3.96 |
Stock Profile
Antigenics, Inc., a biotechnology company, engages in the research and development of technology and products to treat cancers, infectious diseases, and autoimmune disorders. The company's principal product candidate, Oncophage, a personalized cancer vaccine, is in phase III clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma, as well as in phase I/II trial for lung cancer. Its product portfolio also includes AG-858, a personalized cancer vaccine in a phase II clinical trial for the treatment of chronic myelogenous leukemia; AG-702/AG-707, a therapeutic vaccine program in phase I clinical development for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for colorectal cancer and other solid tumors. The company was founded as Antigenics L.L.C. in 1994 and changed its name to Antigenics, Inc. in 2000. Antigenics is headquartered in New York City.
